Media stories about MannKind (NASDAQ:MNKD) have been trending somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MannKind earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.9371757351571 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities analysts have weighed in on MNKD shares. HC Wainwright reaffirmed a “buy” rating on shares of MannKind in a report on Tuesday, October 24th. BidaskClub downgraded shares of MannKind from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Maxim Group reissued a “hold” rating on shares of MannKind in a report on Wednesday, November 1st. Zacks Investment Research downgraded shares of MannKind from a “hold” rating to a “sell” rating in a report on Wednesday, December 13th. Finally, ValuEngine raised shares of MannKind from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $1.89.
MannKind (MNKD) opened at $2.57 on Wednesday. MannKind has a 1-year low of $0.67 and a 1-year high of $6.96. The company has a debt-to-equity ratio of -0.43, a current ratio of 0.31 and a quick ratio of 0.28. The company has a market cap of $299.55, a price-to-earnings ratio of -9.52 and a beta of 3.18.
In related news, VP Stuart A. Tross bought 39,840 shares of the stock in a transaction dated Thursday, December 21st. The shares were purchased at an average price of $2.52 per share, with a total value of $100,396.80. Following the completion of the acquisition, the vice president now owns 59,840 shares of the company’s stock, valued at $150,796.80. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 1.10% of the stock is currently owned by insiders.
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.